Table 2.
Factors associated with virological clearance at T7 (negative antigenic or RNA nasopharyngeal swab at day 7 after beginning of antiviral treatment) by fitting a logistic regression analysis
| Parameters | OR | 95% CI | p values | AOR | 95% CI | p values |
|---|---|---|---|---|---|---|
| Age: | ||||||
| Each year more | 0.978 | 0.963–0.994 | 0.007 | 0.984 | 0.967–1.001 | 0.069 |
| Sex: | 0.493–1.336 | 0.412 | ||||
| Female | 1 | |||||
| Male | 0.812 | |||||
| Vaccination: | ||||||
| > 120 days | 1 | |||||
| ≤ 120 days | 0.735 | 0.424–1.275 | 0.273 | |||
| Immunodeficiency: | ||||||
| Yes | 1 | 1 | ||||
| No | 0.752 | 0.365–1.550 | 0.440 | 1.295 | 0.574–2.924 | 0.534 |
| Days from symptoms onset to treatment: | ||||||
| Each day more | 0.992 | 0.968–1.018 | 0.543 | |||
| Antiviral treatment: | ||||||
| Nirmatrelvir/ritonavir | 1 | < 0.001 | 1 | < 0.001 | ||
| Remdesivir | 0.393 | 0.220–0.705 | 0.002 | 0.445 | 0.240–0.826 | 0.010 |
| Molnupiravir | 0.206 | 0.099–0.428 | < 0.001 | 0.222 | 0.105–0.472 | < 0.001 |
Multivariable logistic regression model is adjusted for age and immunodeficiency
OR odds ratio, AOR adjusted odds ratio, 95%CI 95% confidence interval